Autologous stem cell transplantation in myeloma: The St. James's Hospital experience, 1997-2003

P. J. Hayden, A. O'Driscoll, N. Gardiner, Ronan T Swords, J. Sargent, F. Ni Ainle, A. Fortune, P. T. Murphy, M. Leahy, F. Jackson, M. Ryan, B. Hennessy, M. Cahill, G. M. Crotty, H. Enright, E. Conneally, E. Vandenberghe, S. R. McCann, P. V. Browne

Research output: Contribution to journalArticle

Abstract

Background: High-dose treatment with a utologous stem cell transplantation (ASCT) has become the standard of care for patients with myeloma below the age of 65 years. Aims: We report an audit of 60 patients (median age: 52.5 years) who underwent ASCT in the National Bone Marrow Transplant centre in St James's Hospital in Dublin between 1997 and 2003 inclusive. Methods: Clinical and laboratory data were retrieved from patient medical records and hospital information management systems. Results: Thirty-six patients had IgG, 11 IgA, 1 IgD, 9 light chain and 3 non-secretory MM. Fifty-seven (95%) patients received anthracycline-corticosteroid combination chemotherapy prior to autografting. There was no transplant-related mortality (TRM). Complete (CR) and Partial Responses (PR) were seen in 16 (29.6%) and 29 (53.7%) of those evaluable (n=54 (90%)). The actuarial Progression-Free (PFS) and Overall Survival (OS) rates at five years are 13% and 55% respectively. Conclusion: Centre outcome is comparable to published international series and supports the use of ASCT in the treatment of this malignancy.

Original languageEnglish
Pages (from-to)26-32
Number of pages7
JournalIrish Journal of Medical Science
Volume174
Issue number2
StatePublished - Apr 1 2005
Externally publishedYes

Fingerprint

Stem Cell Transplantation
Hospital Information Systems
Transplants
Immunoglobulin D
Information Management
Autologous Transplantation
Anthracyclines
Standard of Care
Combination Drug Therapy
Immunoglobulin A
Medical Records
Adrenal Cortex Hormones
Survival Rate
Immunoglobulin G
Bone Marrow
Light
Mortality
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hayden, P. J., O'Driscoll, A., Gardiner, N., Swords, R. T., Sargent, J., Ni Ainle, F., ... Browne, P. V. (2005). Autologous stem cell transplantation in myeloma: The St. James's Hospital experience, 1997-2003. Irish Journal of Medical Science, 174(2), 26-32.

Autologous stem cell transplantation in myeloma : The St. James's Hospital experience, 1997-2003. / Hayden, P. J.; O'Driscoll, A.; Gardiner, N.; Swords, Ronan T; Sargent, J.; Ni Ainle, F.; Fortune, A.; Murphy, P. T.; Leahy, M.; Jackson, F.; Ryan, M.; Hennessy, B.; Cahill, M.; Crotty, G. M.; Enright, H.; Conneally, E.; Vandenberghe, E.; McCann, S. R.; Browne, P. V.

In: Irish Journal of Medical Science, Vol. 174, No. 2, 01.04.2005, p. 26-32.

Research output: Contribution to journalArticle

Hayden, PJ, O'Driscoll, A, Gardiner, N, Swords, RT, Sargent, J, Ni Ainle, F, Fortune, A, Murphy, PT, Leahy, M, Jackson, F, Ryan, M, Hennessy, B, Cahill, M, Crotty, GM, Enright, H, Conneally, E, Vandenberghe, E, McCann, SR & Browne, PV 2005, 'Autologous stem cell transplantation in myeloma: The St. James's Hospital experience, 1997-2003', Irish Journal of Medical Science, vol. 174, no. 2, pp. 26-32.
Hayden PJ, O'Driscoll A, Gardiner N, Swords RT, Sargent J, Ni Ainle F et al. Autologous stem cell transplantation in myeloma: The St. James's Hospital experience, 1997-2003. Irish Journal of Medical Science. 2005 Apr 1;174(2):26-32.
Hayden, P. J. ; O'Driscoll, A. ; Gardiner, N. ; Swords, Ronan T ; Sargent, J. ; Ni Ainle, F. ; Fortune, A. ; Murphy, P. T. ; Leahy, M. ; Jackson, F. ; Ryan, M. ; Hennessy, B. ; Cahill, M. ; Crotty, G. M. ; Enright, H. ; Conneally, E. ; Vandenberghe, E. ; McCann, S. R. ; Browne, P. V. / Autologous stem cell transplantation in myeloma : The St. James's Hospital experience, 1997-2003. In: Irish Journal of Medical Science. 2005 ; Vol. 174, No. 2. pp. 26-32.
@article{7d9b2fb1c2c54b50ab67d257eb733dd5,
title = "Autologous stem cell transplantation in myeloma: The St. James's Hospital experience, 1997-2003",
abstract = "Background: High-dose treatment with a utologous stem cell transplantation (ASCT) has become the standard of care for patients with myeloma below the age of 65 years. Aims: We report an audit of 60 patients (median age: 52.5 years) who underwent ASCT in the National Bone Marrow Transplant centre in St James's Hospital in Dublin between 1997 and 2003 inclusive. Methods: Clinical and laboratory data were retrieved from patient medical records and hospital information management systems. Results: Thirty-six patients had IgG, 11 IgA, 1 IgD, 9 light chain and 3 non-secretory MM. Fifty-seven (95{\%}) patients received anthracycline-corticosteroid combination chemotherapy prior to autografting. There was no transplant-related mortality (TRM). Complete (CR) and Partial Responses (PR) were seen in 16 (29.6{\%}) and 29 (53.7{\%}) of those evaluable (n=54 (90{\%})). The actuarial Progression-Free (PFS) and Overall Survival (OS) rates at five years are 13{\%} and 55{\%} respectively. Conclusion: Centre outcome is comparable to published international series and supports the use of ASCT in the treatment of this malignancy.",
author = "Hayden, {P. J.} and A. O'Driscoll and N. Gardiner and Swords, {Ronan T} and J. Sargent and {Ni Ainle}, F. and A. Fortune and Murphy, {P. T.} and M. Leahy and F. Jackson and M. Ryan and B. Hennessy and M. Cahill and Crotty, {G. M.} and H. Enright and E. Conneally and E. Vandenberghe and McCann, {S. R.} and Browne, {P. V.}",
year = "2005",
month = "4",
day = "1",
language = "English",
volume = "174",
pages = "26--32",
journal = "The Dublin Journal of Medical and Chemical Science",
issn = "0332-1029",
publisher = "Springer London",
number = "2",

}

TY - JOUR

T1 - Autologous stem cell transplantation in myeloma

T2 - The St. James's Hospital experience, 1997-2003

AU - Hayden, P. J.

AU - O'Driscoll, A.

AU - Gardiner, N.

AU - Swords, Ronan T

AU - Sargent, J.

AU - Ni Ainle, F.

AU - Fortune, A.

AU - Murphy, P. T.

AU - Leahy, M.

AU - Jackson, F.

AU - Ryan, M.

AU - Hennessy, B.

AU - Cahill, M.

AU - Crotty, G. M.

AU - Enright, H.

AU - Conneally, E.

AU - Vandenberghe, E.

AU - McCann, S. R.

AU - Browne, P. V.

PY - 2005/4/1

Y1 - 2005/4/1

N2 - Background: High-dose treatment with a utologous stem cell transplantation (ASCT) has become the standard of care for patients with myeloma below the age of 65 years. Aims: We report an audit of 60 patients (median age: 52.5 years) who underwent ASCT in the National Bone Marrow Transplant centre in St James's Hospital in Dublin between 1997 and 2003 inclusive. Methods: Clinical and laboratory data were retrieved from patient medical records and hospital information management systems. Results: Thirty-six patients had IgG, 11 IgA, 1 IgD, 9 light chain and 3 non-secretory MM. Fifty-seven (95%) patients received anthracycline-corticosteroid combination chemotherapy prior to autografting. There was no transplant-related mortality (TRM). Complete (CR) and Partial Responses (PR) were seen in 16 (29.6%) and 29 (53.7%) of those evaluable (n=54 (90%)). The actuarial Progression-Free (PFS) and Overall Survival (OS) rates at five years are 13% and 55% respectively. Conclusion: Centre outcome is comparable to published international series and supports the use of ASCT in the treatment of this malignancy.

AB - Background: High-dose treatment with a utologous stem cell transplantation (ASCT) has become the standard of care for patients with myeloma below the age of 65 years. Aims: We report an audit of 60 patients (median age: 52.5 years) who underwent ASCT in the National Bone Marrow Transplant centre in St James's Hospital in Dublin between 1997 and 2003 inclusive. Methods: Clinical and laboratory data were retrieved from patient medical records and hospital information management systems. Results: Thirty-six patients had IgG, 11 IgA, 1 IgD, 9 light chain and 3 non-secretory MM. Fifty-seven (95%) patients received anthracycline-corticosteroid combination chemotherapy prior to autografting. There was no transplant-related mortality (TRM). Complete (CR) and Partial Responses (PR) were seen in 16 (29.6%) and 29 (53.7%) of those evaluable (n=54 (90%)). The actuarial Progression-Free (PFS) and Overall Survival (OS) rates at five years are 13% and 55% respectively. Conclusion: Centre outcome is comparable to published international series and supports the use of ASCT in the treatment of this malignancy.

UR - http://www.scopus.com/inward/record.url?scp=22744450232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22744450232&partnerID=8YFLogxK

M3 - Article

C2 - 16094909

AN - SCOPUS:22744450232

VL - 174

SP - 26

EP - 32

JO - The Dublin Journal of Medical and Chemical Science

JF - The Dublin Journal of Medical and Chemical Science

SN - 0332-1029

IS - 2

ER -